DE17196350T1 - Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden - Google Patents

Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden Download PDF

Info

Publication number
DE17196350T1
DE17196350T1 DE17196350.7T DE17196350T DE17196350T1 DE 17196350 T1 DE17196350 T1 DE 17196350T1 DE 17196350 T DE17196350 T DE 17196350T DE 17196350 T1 DE17196350 T1 DE 17196350T1
Authority
DE
Germany
Prior art keywords
antibodies
antibody
factor
host cell
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE17196350.7T
Other languages
English (en)
Inventor
Yung-Hsiang Kao
Melody Trexher Schmidt
Michael W. Laird
Rita L. Wong
Daniel P. Hewitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE17196350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE17196350T1 publication Critical patent/DE17196350T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

Verfahren zur Prävention der Reduktion einer Disulfidbindung in einem in einer rekombinanten Wirtszelle exprimierten Polypeptid, umfassend das Ergänzen der Zellkulturflüssigkeit der rekombinanten Wirtszelle vor oder nach dem Gewinnen derselben mit einem Thioredoxin-Inhibitor.

Claims (25)

  1. Verfahren zur Prävention der Reduktion einer Disulfidbindung in einem in einer rekombinanten Wirtszelle exprimierten Polypeptid, umfassend das Ergänzen der Zellkulturflüssigkeit der rekombinanten Wirtszelle vor oder nach dem Gewinnen derselben mit einem Thioredoxin-Inhibitor.
  2. Verfahren nach Anspruch 1, wobei der Thioredoxin-Inhibitor Folgendes ist: (i) ein direkter Inhibitor von Thioredoxin; (ii) ein spezifischer Inhibitor von Thioredoxinreduktase, (iii) ein Metallion; (iv) ein Inhibitor von G6PD; (v) ein Inhibitor von Hexokinaseaktivität; (vi) Cystin, Cystein oder oxidiertes Glutathion; (vii) ein Antikörper, der spezifisch an eine Thioredoxinreduktase bindet; oder (viii) eine Maßnahme, die indirekt zur Hemmung von Thioredoxinaktivität führt.
  3. Verfahren nach Anspruch 2(i), wobei der Thioredoxin-Inhibitor ein Alkyl-2-imidazolyldisulfid oder ein Naphthochinonspiroketal-Derivat ist.
  4. Verfahren nach Anspruch 2(ii), wobei der Thioredoxin-Inhibitor ein Goldkomplex ist.
  5. Verfahren nach Anspruch 4, wobei der Goldkomplex Aurothioglucose (ATG) oder Aurothiomalat (ATM) ist und das ATG oder das ATM gegebenenfalls in einer Konzentration (a) zwischen etwa 0,1 mM und etwa 1 mM oder (b) von zumindest dem 4-Fachen der Thioredoxinreduktase-Konzentration in der Kulturflüssigkeit vor oder nach dem Gewinnen derselben zugesetzt wird.
  6. Verfahren nach Anspruch 2(iii), wobei das Metallion aus der aus Hg2+, Cu2+, Zn2+, Co2+ und Mn2+ bestehenden Gruppe ausgewählt ist.
  7. Verfahren nach Anspruch 6, wobei das Metallion Cu2+ ist, das in Form von Kupfer(II)-sulfat vorliegt.
  8. Verfahren nach Anspruch 7, wobei das Kupfer(II)-sulfat (a) als Pentahydrat oder in wasserfreier Form vorliegt; (b) in einer Konzentration zwischen etwa 5 µM und etwa 100 µM zugesetzt wird; (c) in einer Konzentration zwischen etwa 10 µM und etwa 80 µM zugesetzt wird; (d) in einer Konzentration zwischen etwa 15 µM und etwa 50 µM zugesetzt wird; oder (e) in einer Konzentration von zumindest dem 2-Fachen der Thioredoxin-Konzentration in der Kulturflüssigkeit vor oder nach dem Gewinnen derselben zugesetzt wird
  9. Verfahren nach Anspruch 2(iv), wobei der Thioredoxin-Inhibitor aus der aus Pyridoxal-5'-phosphat, 1-Fluor-2,4-dinitrobenzol, Dehydroepiandrosteron (DHEA) und Epiandrosteron (EA) bestehenden Gruppe ausgewählt ist.
  10. Verfahren nach Anspruch 9, wobei das DHEA in einer Konzentration (a) zwischen etwa 0,05 mM und etwa 5 mM oder (b) zwischen etwa 0,1 mM und etwa 2,5 mM zugesetzt wird.
  11. Verfahren nach Anspruch 2(v), wobei der Thioredoxin-Inhibitor (a) ein Metallionen-Chelatbildner ist; (b) aus der aus Sorbose-1-phosphat, Polyphosphaten, 6-Desoxy-6-fluor-glucose, 2-C-Hydroxymethylglucose, Xylose oder Lyxose bestehenden Gruppe ausgewählt ist.
  12. Verfahren nach Anspruch 11(a), wobei der Metallionen-Chelatbildner Ethylendiamintetraessigsäure (EDTA) ist.
  13. Verfahren nach Anspruch 12, wobei die EDTA in einer Konzentration (i) zwischen etwa 5 mM und etwa 60 mM, (ii) zwischen etwa 10 mM und etwa 50 mM; oder (iii) zwischen etwa 20 mM und etwa 40 mM zugesetzt wird.
  14. Verfahren nach Anspruch 2(vi), wobei das Cystin, Cystein oder oxidierte Glutathion in einer Konzentration von zumindest etwa dem 40-Fachen der Konzentration des Polypeptids in der Kulturflüssigkeit vor oder nach dem Gewinnen derselben zugesetzt wird.
  15. Verfahren nach Anspruch 2(viii), wobei die Maßnahme das Belüften der gewonnenen Kulturflüssigkeit der rekombinanten Wirtszelle oder das Senken des pHs der gewonnenen Kulturflüssigkeit der rekombinanten Wirtszellen ist.
  16. Verfahren nach einem der Ansprüche 1 bis 14, das weiters den Schritt (i) des Belüftens der gewonnenen Kulturflüssigkeit der rekombinanten Wirtszelle oder (ii) des Senkens des pHs der gewonnenen Kulturflüssigkeit der rekombinanten Wirtszellen umfasst.
  17. Verfahren zur Verhinderung der Reduktion einer Disulfidbindung eines Antikörpers oder eines biologisch funktionellen Fragments davon, der/das in einer rekombinanten Wirtszelle exprimiert wird, umfassend das Verringern des Expressionslevels eines Enyzms des Trx-Systems in der eukaryotischen Wirtszelle durch: (a) ein Nucleinsäuremolekül, das ein Antisense-Nucleotid umfasst, oder (b) eine interferierende RNA; und das Gewinnen des Antikörpers oder dessen biologisch funktionellen Fragments, wodurch die Reduktion der Disulfidbindung des Antikörpers oder dessen biologisch funktionellen Fragments im geernteten Zellkulturfluid (HCCF) verhindert wird.
  18. Verfahren nach Anspruch 17, wobei das Enzym Thioredoxinreduktase, G6PD oder Hexokinase ist.
  19. Verfahren nach einem der Ansprüche 1 bis 16, wobei das Polypeptid ein Antikörper oder ein biologisch funktionelles Fragment eines Antikörpers ist.
  20. Verfahren nach einem der Ansprüche 17 bis 19, wobei (i) das biologisch funktionelle Fragment des Antikörpers aus der aus Fab, Fab‘, F(ab‘)2, scFv, (scFv)2, dAb, Fragmenten komplementaritätsbestimmender Regionen (CDR), unverzweigten Antikörpern, Einzelketten-Antikörpermolekülen, Minibodys, Diabodys und multispezifischen Antikörpern, gebildet aus Antikörperfragmenten, bestehenden Gruppe ausgewählt ist oder (ii) der Antikörper oder das Antikörperfragment ein therapeutischer Antikörper oder ein biologisch funktionelles Fragment davon ist.
  21. Verfahren nach Anspruch 20(ii), wobei der therapeutische Antikörper aus der aus Anti-HER2-Antikörpern; Anti-CD20-Antikörpern; Anti-IL-8-Antikörpern; Anti-VEGF-Antikörpern; Anti-CD40-Antikörpern; Anti-CD11a-Antikörpern; Anti-CD18-Antikörpern; Anti-IgE-Antikörpern; Anti-Apo-2-Rezeptor-Antikörpern; Anti-Gewebefaktor-(TF-) Antikörpern; Anti-Mensch-α4β7-Integrin-Antikörpern; Anti-EGFR-Antikörpern; Anti-CD3-Antikörpern; Anti-CD25-Antikörpern; Anti-CD4-Antikörpern; Anti-CD52-Antikörpern; Anti-Fc-Rezeptor-Antikörpern; Anti-karzinoembryonisches-Antigen- (CEA-) Antikörpern; Antikörpern, die gegen Brustepithelzellen gerichtet sind; Antikörpern, die an Dickdarmkarzinomzellen binden; Anti-CD38-Antikörpern; Anti-CD33-Antikörpern; Anti-CD22-Antikörpern; Anti-EpCAM-Antikörpern; Anti-GpIIb/IIIa-Antikörpern; Anti-RSV-Antikörpern; Anti-CMV-Antikörpern; Anti-HIV-Antikörpern; Anti-Hepatitis-Antikörpern; Anti-CA125-Antikörpern; Anti-αvβ3-Antikörpern; Anti-Human-Nierenzellenkarzinom-Antikörpern; Anti-Humen-17-1A-Antikörpern; Anti-Humen-Kolorektaltumor-Antikörpern; Anti-Human-Melanom-Antikörper R24, der gegen GD3-Gangliosid gerichtet ist; Anti-Human-Plattenepithelzellkarzinom-; und Anti-Human-Leukozytenantigen- (HLA-) Antikörpern und Anti-HLA-DR-Antikörpern bestehenden Gruppe ausgewählt ist.
  22. Verfahren nach Anspruch 20(ii), wobei der therapeutische Antikörper ein Antikörper ist, der an Folgendes bindet: (a) einen HER-Rezeptor, wobei der HER-Rezeptor gegebenenfalls HER2 ist und der therapeutische Antikörper eine Sequenz einer variablen Schwer- und/oder Leichtkettendomäne umfasst, die aus der aus Seq.-ID Nr. 16, 17, 18 und 19 bestehenden Gruppe ausgewählt ist; (b) VEGF, wobei der therapeutische Antikörper gegebenenfalls eine Sequenz einer variablen Schwer- und/oder Leichtkettendomäne umfasst, die aus der aus Seq.-ID Nr. 20 bis 55 bestehenden Gruppe ausgewählt ist; (c) IgE; (d) CD20, wobei der therapeutische Antikörper gegebenenfalls eine Sequenz einer variablen Schwer- und/oder Leichtkettendomäne umfasst, die aus der aus Seq.-ID Nr. 1 bis 15 bestehenden Gruppe ausgewählt ist; (e) CD11a, wobei der therapeutische Antikörper gegebenenfalls eine Sequenz einer variablen Schwer- und/oder Leichtkettendomäne umfasst, die aus der aus Seq.-ID Nr. 26 bis 29 bestehenden Gruppe ausgewählt ist; (f) CD40; oder (g) DR5, wobei der therapeutische Antikörper gegebenenfalls aus der aus den Apomabs 1.1, 2.1, 3.1, 4.1, 5.1, 5.2, 5.3, 6.1, 6.2, 6.3, 7.1, 7.2, 7.3, 8.1, 8.3, 9.1, 1.2, 2.2, 3.2, 4.2, 5.2, 6.2, 7.2, 8.2, 9.2, 1.3, 2.2, 3.3, 4.3, 5.3, 6.3, 7.3, 8.3, 9.3 und 25.3 bestehenden Gruppe ausgewählt ist.
  23. Verfahren nach einem der Ansprüche 1 bis 16, wobei das Polypeptid ein therapeutisches Polypeptid ist und wobei das therapeutische Polypeptid gegebenenfalls aus der aus einem Wachstumshormon, einschließlich des menschlichen Wachstumshormons und des Rinderwachstumshormons; dem Wachstumshormon-freisetzenden Faktor; Parathormon; Schilddrüsenstimulationshormon; Lipoproteinen; α-1-Antitrypsin; Insulin-A-Kette; Insulin-B-Kette; Proinsulin; follikelstimulierendem Hormon; Calcitonin; luteinisierendem Hormon; Glucagon; Gerinnungsfaktoren wie Faktor VIIIC, Faktor IX, Gewebefaktor und von-Willebrand-Faktor; Anti-Gerinnungsfaktoren wie Protein C; atrialem natriuretischem Faktor; Lungentensid; einem Plasminogenaktivator wie Urokinase oder menschlichem Urin- oder Gewebetyp-Plasminogen-Aktivator (t-PA); Bombesin; Thrombin; hämatopoietischem Wachstumsfaktor; Tumornekrosefaktor-α und -β; Enkephalinase; RANTES (reguliert bei Aktivierung, normalerweise T-Zellen-exprimiert und -sekretiert); menschlichem Makrophagenentzündungsprotein (MIP-1-α); einem Serumalbumin wie menschlichem Serumalbumin; Müllerscher Inhibitionssubstanz; Relaxin-A-Kette; Relaxin-B-Kette; Prorelaxin; Mäuse-Gonadotropin-assoziiertem Peptid; einem mikrobiellen Protein wie β-Lactamase; DNase; IgE; einem zytotoxischen T-Lymphozyten-assoziierten Antigen (CTLA) wie CTLA-4; Inhibin; Activin; Gefäßendothelwachstumsfaktor (VEGF); Rezeptoren für Hormone oder Wachstumsfaktoren; Protein A oder D; rheumatoiden Faktoren; einem neurotrophen Faktor wie knochenabgeleiteter neurotropher Faktor (BDNF), Neurotrophin-3, -4, -5 oder -6 (NT-3, NT-4, NT-5 oder NT-6) oder einem Nervenwachstumsfaktor wie NGF-β; plättchenabgeleitetem Wachstumsfaktor (PDGF); Fibroblastenwachstumsfaktor wie aFGF und bFGF; Epidermiswachstumsfaktor (EGF); transformierendem Wachstumsfaktor (TGF) wie TGF-α und TGF-β, einschließlich TGF-β1, TGF-β2, TGF-β3, TGF-β4 oder TGF-β5; insulinähnlichem Wachstumsfaktor-I und -II (IGF-I und IGF-II); des(1-3)-IGF-I (Hirn-IGF-I); Bindungsproteinen für insulinähnlichen Wachstumsfaktor; CD-Proteinen wie CD3, CD4, CD8, CD19, CD20, CD34 und CD40; Erythropoietin; osteoinduktiven Faktoren; Immuntoxinen; einem knochenmorphogenetischen Protein (BMP); einem Interferon wie Interferon-α, -β und -γ; koloniestimulierenden Faktoren (CSFs), z.B. M-CSF, GM-CSF und G-CSF; Interleukinen (ILs), z.B. IL-1 bis IL-10; Superoxiddismutase; T-Zellen-Rezeptoren; Oberflächenmembranproteinen; Abbaubeschleunigungsfaktor; viralen Antigenen wie z.B. eines Teils der AIDS-Hülle; Transportproteinen; Homing-Rezeptoren; Addressinen; Regulationsproteinen; Integrinen wie CD11a, CD11b, CD11c, CD18, einem ICAM, VLA-4 und VCAM; einem tumorassoziierten Antigen wie HER2-, HER3- oder HER4-Rezeptor; und Fragmenten der Polypeptide bestehenden Gruppe ausgewählt ist.
  24. Verfahren nach einem der Ansprüche 1 bis 23, wobei die rekombinante Wirtszelle (i) eine eukaryotische Wirtszelle oder (ii) eine prokaryotische Wirtszelle ist.
  25. Verfahren nach Anspruch 24, wobei die eukaryotische Wirtszelle eine Säugetier-Wirtszelle ist und gegebenenfalls eine Chinahamster-Eierstock- (CHO-) Zelle ist oder die prokaryotische Wirtszelle eine Bakterienzelle ist und gegebenenfalls eine E.-coli-Zelle ist.
DE17196350.7T 2007-07-09 2008-07-08 Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden Pending DE17196350T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94867707P 2007-07-09 2007-07-09
US948677P 2007-07-09
EP17196350.7A EP3327026B1 (de) 2007-07-09 2008-07-08 Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden

Publications (1)

Publication Number Publication Date
DE17196350T1 true DE17196350T1 (de) 2018-12-27

Family

ID=39791340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE17196350.7T Pending DE17196350T1 (de) 2007-07-09 2008-07-08 Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden

Country Status (24)

Country Link
US (11) US20090053786A1 (de)
EP (7) EP2586788B1 (de)
JP (5) JP5687057B2 (de)
KR (6) KR20190140090A (de)
CN (3) CN112480255A (de)
AU (2) AU2008275229B2 (de)
BR (1) BRPI0812603B1 (de)
CA (2) CA3113365A1 (de)
DE (1) DE17196350T1 (de)
DK (2) DK3327026T3 (de)
ES (4) ES2941738T3 (de)
FI (1) FI3597659T3 (de)
HR (3) HRP20230461T3 (de)
HU (4) HUE037162T2 (de)
IL (6) IL202934B (de)
LT (2) LT3597659T (de)
MX (2) MX2010000196A (de)
PL (4) PL2586788T3 (de)
PT (2) PT3597659T (de)
SG (3) SG10202005450PA (de)
SI (4) SI3327026T1 (de)
TR (1) TR201802088T4 (de)
TW (4) TWI666217B (de)
WO (1) WO2009009523A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201708537A (zh) 2006-09-13 2017-03-01 艾伯維有限公司 細胞培養改良
AU2008275229B2 (en) * 2007-07-09 2014-11-06 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
PT2424889E (pt) * 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
BRPI1012321A8 (pt) * 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
WO2011121560A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN101974535B (zh) * 2010-11-03 2012-12-19 北京天广实生物技术股份有限公司 新型抗ErbB2人源化抗体MIL12的制备及其应用
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN102911265B (zh) * 2011-08-05 2014-02-05 王革 一种人神经生长因子的重组变异体及其制备方法
AU2013240280A1 (en) 2012-03-27 2014-10-16 Genentech, Inc. Improved harvest operations for recombinant proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9976163B2 (en) 2012-10-03 2018-05-22 Kyowa Hakko Kirin Co., Ltd Method for preventing reduction of polypeptide by adding amino acid to culture solution
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3800204A1 (de) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab-varianten und evaluierung davon
WO2015009699A1 (en) * 2013-07-15 2015-01-22 Ketter Patrick Methods and compositions to prevent or treat bacterial infections
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015085003A1 (en) * 2013-12-04 2015-06-11 Immunogen, Inc. Compositions and methods for antibody production
US9620278B2 (en) * 2014-02-19 2017-04-11 General Electric Company System and method for reducing partial discharge in high voltage planar transformers
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US10653794B2 (en) * 2015-08-12 2020-05-19 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
EP4209499A1 (de) 2015-08-13 2023-07-12 Amgen Inc. Geladene tiefenfiltration von antigenbindenden proteinen
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3020990A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Humanized anti-pacap antibodies and uses thereof
KR20230124093A (ko) * 2016-05-10 2023-08-24 제넨테크, 인크. 폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을감소시키기 위한 방법
AU2017262734B2 (en) * 2016-05-10 2020-04-30 Medimmune, Llc Prevention of protein disulfide bond reduction
CA3026589A1 (en) * 2016-06-10 2017-12-14 Lonza Ltd Method for stabilizing proteins
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
CN106366160B (zh) * 2016-10-11 2019-06-14 厦门大学 基于二硫键精准配对构建富含二硫键多肽分子骨架的方法
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
BR112019010943A8 (pt) 2016-11-30 2023-02-07 Oncomed Pharm Inc Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
EP3564367A4 (de) 2016-12-28 2020-08-12 Kyowa Kirin Co., Ltd. Verfahren zur auswahl von zellen
WO2018200430A1 (en) * 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
WO2018208743A1 (en) * 2017-05-09 2018-11-15 Bristol-Myers Squibb Company Method of controlling the formation of pink color during antibody manufacturing
US10913795B2 (en) * 2017-05-17 2021-02-09 Immunogen, Inc. Compositions and methods for antibody production
EP3672981A4 (de) * 2017-08-22 2021-09-15 Biogen MA Inc. Verfahren zur reinigung von antikörpern mit aggregaten mit reduziertem hochmolekularem gewicht
TW201923069A (zh) 2017-10-02 2019-06-16 美商拜耳保健有限責任公司 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法
TW201927335A (zh) * 2017-10-02 2019-07-16 美商拜耳保健有限責任公司 防止雙硫鍵於細胞培養收集物中還原之方法
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
JP2021521873A (ja) * 2018-05-04 2021-08-30 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ 改変された宿主細胞タンパク質プロファイルを有する操作された細胞
WO2020028616A1 (en) * 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
BR112021009036A2 (pt) 2018-11-08 2021-08-24 Sutro Biopharma, Inc. Cepas de e coli apresentando um citoplasma oxidativo
EP3947632A1 (de) 2019-04-01 2022-02-09 The Automation Partnership (Cambridge) Ltd. Betriebsverfahren für ein zellkultivierungssystem
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗ｍＧｌｕＲ５抗体及びその使用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2024058951A1 (en) * 2022-09-15 2024-03-21 Sanofi Methods of determining protein reduction susceptability

Family Cites Families (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US524474A (en) * 1894-08-14 Seed-planter
US670534A (en) * 1900-07-27 1901-03-26 Oliver L Carmical Seeding-machine and fertilizer-distributer.
US1369649A (en) * 1920-01-02 1921-02-22 George A Gieseler Pneumatic conveying mechanism
US2062295A (en) * 1932-11-22 1936-12-01 Niagara Sprayer And Chemical C Crop duster
US2171205A (en) * 1937-08-26 1939-08-29 Louis A Zinke Powder distributing attachment for tractors
US2193738A (en) * 1938-05-21 1940-03-12 Nat Conveyors Co Inc Pneumatic conveyer
US2559183A (en) * 1946-12-10 1951-07-03 Lawton L Barnett Transplanter drill set
US2671690A (en) * 1948-02-21 1954-03-09 Ehrenkrook Karl Von Forced air sprayer and duster
US2937049A (en) * 1949-10-18 1960-05-17 Osawa Hirosaburo Method of and an apparatus for carrying coals out of a vertical shaft with the aid of heavy liquid in the coal mine
US2814531A (en) * 1956-04-27 1957-11-26 Clough Equipment Co Balanced pneumatic conveying systems for pulverulent material
US3207560A (en) * 1962-12-26 1965-09-21 Monsanto Co Unloading device
US3197261A (en) * 1964-03-09 1965-07-27 Simpson Herbert Corp System for feeding and transporting materials
US3386474A (en) * 1965-05-26 1968-06-04 Chemagro Corp Diverter valve for finely divided solids
US3515315A (en) * 1966-01-24 1970-06-02 Kidd Designs Ltd Archie Combined seed and fertilizer drills for agricultural use
US3387895A (en) * 1966-12-29 1968-06-11 Combustion Eng Non-clogging splitter unit for dividing the flow of fluid-conveyed material
FR1558490A (de) * 1967-12-27 1969-02-28
US3543704A (en) * 1968-08-05 1970-12-01 Deere & Co Seed planter
US3845702A (en) 1970-04-01 1974-11-05 Mies Filter Prod Inc Apparatus for cooking chicken
DE2440888C3 (de) * 1974-08-27 1978-11-23 Waeschle Maschinenfabrik Gmbh, 7980 Ravensburg Anlage zum aufeinanderfolgenden Beschicken mehrerer, hintereinander an eine pneumatische Förderleitung über Abscheider angeschlossener Entnahmestationen mit Schüttgut
US4049494A (en) 1975-09-04 1977-09-20 The United States Of America As Represented By The Secretary Of Agriculture Vaccine production process
US4036408A (en) * 1975-12-24 1977-07-19 Acf Industries, Incorporated Hopper having means for directing blasts of gas to a discharge outlet or the hopper
US4280419A (en) * 1977-03-21 1981-07-28 International Harvester Company Pneumatic system for conveying granular material
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4200412A (en) * 1978-04-20 1980-04-29 Dynamic Air Incorporated Control for pneumatic conveying system
US4264243A (en) * 1979-01-04 1981-04-28 Dundee Cement Company Constant vacuum barge unloading system
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4244522A (en) * 1979-08-31 1981-01-13 Deere & Company Liquid storage and distribution apparatus for agricultural implements
CA1126587A (en) * 1980-07-11 1982-06-29 Daniel W. Kelm Seed cup assembly
US4413935A (en) * 1981-06-29 1983-11-08 Combustion Engineering, Inc. Flow splitter for dividing a stream of pulverulent material into multiple streams
GB2112506A (en) * 1981-12-30 1983-07-20 Shell Int Research Distributing valve
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
DE3239897A1 (de) * 1982-10-28 1984-05-03 Trützschler GmbH & Co KG, 4050 Mönchengladbach Verfahren und vorrichtung zur foerderung von faserfoermigen stoffen, insbesondere von in luft schwebend gefoerderten textilen faserflocken bei spinnereivorbereitungsmaschinen
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4562779A (en) * 1984-01-26 1986-01-07 Briggs Manufacturing, Inc. Foldable drill implement
DE3420616A1 (de) * 1984-06-02 1985-12-05 Alb. Klein Gmbh & Co Kg, 5241 Niederfischbach Vorrichtung und verfahren zur steuerung eines schleusvorganges fuer ein haufwerk von schuettgutpartikeln
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4652630A (en) 1985-02-22 1987-03-24 Monsanto Company Method of somatotropin naturation
US5523215A (en) 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4738770A (en) * 1985-11-25 1988-04-19 Cities Service Oil And Gas Corp. Apparatus and method of removal of catalyst blockage from reactor recycle pumps
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4779765A (en) * 1987-04-13 1988-10-25 Deere & Company Fertilizer divider for dual air system
US4793743A (en) * 1987-04-29 1988-12-27 Morris Rod-Weeder Company Ltd. Air seeder purging system
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US4872785A (en) * 1988-01-22 1989-10-10 Schrage Timothy L Shut-off means for air-actuated planter
US4843983A (en) * 1988-02-02 1989-07-04 Deere & Company Pneumatic manifold quick coupling
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
EP0435911B1 (de) 1988-09-23 1996-03-13 Cetus Oncology Corporation Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DK167639B1 (da) * 1988-11-16 1993-12-06 Kongskilde Maskinfabrik As Maskine til saaning af granuleret materiale
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394538B1 (de) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh Hefezellen der Gattung-Schwanniomyces
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991001367A1 (en) 1989-07-20 1991-02-07 Bioeng, Inc. Supercritical fluid disruption of and extraction from microbial cells
DE69017793T2 (de) 1989-08-21 1995-08-24 Takeda Chemical Industries Ltd Produktion von menschlichen Nervenwachstumsfaktoren.
US5033914A (en) * 1989-09-29 1991-07-23 Cyclonaire Corporation High efficiency feeder apparatus for pneumatic conveying lines
EP1241258A3 (de) 1989-10-16 2003-12-10 Amgen Inc. Stamzellfaktor
GB2237288A (en) 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
CA2086417C (en) 1990-06-29 1999-07-06 Biosource Technologies, Inc. Melanin production by transformed organisms
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5069583A (en) * 1990-10-26 1991-12-03 Caldwell Lawrence G Device for changing flow paths in a pneumatic conveying system
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
US5494381A (en) * 1991-04-11 1996-02-27 The Young Industries, Inc. Apparatus and method for pneumatically conveying bulk materials
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US5161473A (en) * 1991-05-17 1992-11-10 Deere & Company Seed distribution system and method for a seeding implement
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2296839T3 (es) 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5240355A (en) * 1992-05-22 1993-08-31 Nol-Tec Systems, Inc. Dense phase transporter pneumatic conveying system
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE149570T1 (de) * 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5379706A (en) * 1993-04-07 1995-01-10 Agco Corporation Seed distribution system for planters and drills
AU5752594A (en) * 1993-04-20 1994-11-03 Deere & Company Air separation tube for a pneumatic delivery system
US5407305A (en) * 1993-04-29 1995-04-18 Semco, Inc. Continuous dense phase conveying method utilizing high pressure gas at predetermined gas pressures within a conveying pipe
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2176811C (en) 1993-12-10 2008-01-29 David Tai Wai Fei Methods for diagnosis of allergy and screening of anti-allergy therapeutics
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
GB9413127D0 (en) 1994-06-30 1994-08-24 Philips Electronics Uk Ltd Data processing apparatus
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5575225A (en) * 1995-02-27 1996-11-19 Unverferth Manufacturing Company, Inc. Air-powered apparatus for filling grain drills and method of using same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
EP1709970A1 (de) 1995-04-27 2006-10-11 Abgenix, Inc. Menschliche Antikörper gegen EGFR, von immunisierten transgenen Mäusen produziert
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2221234A1 (en) * 1995-05-15 1996-11-21 Cedars-Sinai Medical Center Compositions and methods for inhibiting xenograft rejection
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5830761A (en) 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5854067A (en) * 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
EP1297847A3 (de) 1996-01-23 2003-05-07 Genentech, Inc. Antikörper gegen CD18 bei Gehirnschlag
US5813801A (en) * 1996-06-28 1998-09-29 Mac Equipment, Inc. Dense phase particulate conveying system and method with continuous air leakage management
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5749682A (en) * 1996-09-10 1998-05-12 Renfro Corporation Article collection and distribution system
US5912327A (en) 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
JP2001503401A (ja) 1996-10-24 2001-03-13 ヴァンダービルト・ユニバーシティ 直接タンパク質送達することが困難な領域での遺伝子送達及び発現
JP4671372B2 (ja) 1996-11-15 2011-04-13 ジェネンテック， インコーポレイテッド ニューロトロフィンの精製
SI1897890T1 (sl) * 1996-11-27 2010-03-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
JP3778945B2 (ja) 1996-11-27 2006-05-24 ジェネンテック・インコーポレーテッド ヒト化抗ＣＤ１１ａ抗体
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5927217A (en) * 1997-06-16 1999-07-27 Conserva Pak Seeding Systems Metering particulate material
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
EP0994903B1 (de) 1997-06-24 2005-05-25 Genentech, Inc. Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US5878679A (en) * 1997-08-18 1999-03-09 Deere & Company Product disconnect for metering device
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
CA2319710A1 (en) 1998-01-30 1999-08-05 Jim A. Wright Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ATE244758T1 (de) 1998-04-21 2003-07-15 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US6047652A (en) * 1998-05-12 2000-04-11 Case Corporation Seed planter distribution system
NZ528701A (en) 1998-05-15 2005-02-25 Genentech Inc Novel PRO474 polypeptides and nucleic acids encoding same with similarity with dehydrogenase
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
AU739394B2 (en) 1998-08-27 2001-10-11 Lg Chemical Limited Process for the preparation of active somatotropin from inclusion bodies
WO2000015665A2 (en) 1998-09-14 2000-03-23 Pedersen Lars Oestergaard A method of producing a functional immunoglobulin superfamily protein
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US6298797B1 (en) * 1998-11-05 2001-10-09 Flexi-Coil Ltd. Nurse inductor apparatus for air seeders
DK1616572T3 (da) 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
MY155913A (en) 1998-11-09 2015-12-15 Biogen Inc Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
EP2364997A3 (de) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptidvarianten mit veränderter Effektorfunktion
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1035172A3 (de) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethinverbindung und ölige Magentatinte
EP1048732A1 (de) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen
EP1642596A3 (de) 1999-05-07 2006-04-12 Genentech, Inc. Behandlung von Autoimmunkrankheiten mit Antagonisten, die Oberflächenmarker von B Zellen binden
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
MXPA02000419A (es) 1999-07-12 2004-09-10 Genentech Inc Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20.
DK1200179T3 (da) 1999-07-30 2006-09-25 Genentech Inc Ladede filtreringsmembraner og anvendelser deraf
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
WO2001010462A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
US6872563B1 (en) 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
ATE400587T1 (de) 1999-10-29 2008-07-15 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1242610A1 (de) 1999-12-22 2002-09-25 Novo Nordisk A/S Verfahren zur extraktion und rückfaltung von polypeptiden, deren cystinbrücken nicht korrekt verknüpft vorliegen
JP2003528155A (ja) 2000-03-24 2003-09-24 カイロン コーポレイション Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
JP2004500412A (ja) 2000-03-31 2004-01-08 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗ｃｄ２０の併用
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20030009301A1 (en) 2000-05-30 2003-01-09 M.B. Anand Integrated utility meter-reading, billing, payment and usage management system
EP1299128A2 (de) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
AU7013401A (en) 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA03000306A (es) 2000-07-12 2004-04-05 Idec Pharma Corp Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
US7041479B2 (en) * 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US6548276B2 (en) 2000-09-06 2003-04-15 The Board Of Trustees Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
KR20040023565A (ko) 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US20040185535A1 (en) 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
WO2002034790A1 (en) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
US20070292411A1 (en) 2000-11-08 2007-12-20 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EA007388B1 (ru) 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
MXPA03007563A (es) 2001-02-23 2003-12-11 Immunex Corp Recuperacion incrementada de proteinas activas.
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
US20030040095A1 (en) 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
EP1383800A4 (de) 2001-04-02 2004-09-22 Idec Pharma Corp ZUSAMMEN MIT GnTIII EXPRIMIERTE REKOMBINANTE ANTIKÖRPER
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
AU2002315168A1 (en) 2001-06-14 2003-01-02 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003024993A2 (en) 2001-09-20 2003-03-27 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
CA2460206C (en) 2001-10-02 2012-01-24 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US6852680B2 (en) 2001-10-26 2005-02-08 Ethyl Corporation Dithiocarbamates containing alkylthio and hydroxy substituents
US20060040348A1 (en) 2001-11-13 2006-02-23 Minmin Qin Methods for producing and purifying recombinant alpha-L-iduronidase
AU2002362098A1 (en) 2001-12-07 2003-06-23 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
WO2003083056A2 (en) 2002-03-23 2003-10-09 Research Development Foundation Secretion of proteins with multiple disulfide bonds in bacteria and uses thereof
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
EP1498485A4 (de) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk Zellen mit modifiziertem genom
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US20040029229A1 (en) * 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7189811B2 (en) 2002-09-06 2007-03-13 National Institute Of Immunology Process for solubilization of recombinant proteins expressed as inclusion body
SI1561756T1 (sl) * 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
WO2004035608A2 (en) 2002-10-18 2004-04-29 Abgenix, Inc. System and method for cleaving antibodies
WO2004092393A1 (en) 2003-01-09 2004-10-28 Genentech, Inc. Purification of polypeptides
CN100395263C (zh) 2003-01-31 2008-06-18 欧加农股份有限公司 缺氧条件下的蛋白质分离方法
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
WO2005016968A2 (en) * 2003-07-28 2005-02-24 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP1673452B1 (de) 2003-10-10 2015-12-23 Novo Nordisk Health Care AG Verfahren zur produktion eines polypeptids in eukaryontischen zellen im grossmassstab
SI1720979T1 (sl) 2004-03-01 2007-12-31 Ares Trading Sa Uporaba medija za celiäśno kulturo brez seruma zaizdelavo il-18bp pri celicah sesalcev
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
EP1805205A1 (de) 2004-10-22 2007-07-11 Amgen Inc. Verfahren zur rückfaltung von polypeptiden
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
JP2006186521A (ja) 2004-12-27 2006-07-13 Leader Electronics Corp チューナのビットエラーレート（ｂｅｒ）測定の方法および装置
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EP1996697A2 (de) 2006-03-07 2008-12-03 Novartis AG Verhinderung von norvalin- und norleucin-fehlinkorporation in rekombinante proteine
TW201708537A (zh) * 2006-09-13 2017-03-01 艾伯維有限公司 細胞培養改良
JP5732196B2 (ja) 2006-11-01 2015-06-10 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
CN107090482A (zh) 2006-12-29 2017-08-25 细胞基因公司 制备Romidepsin
US8467449B2 (en) * 2007-01-08 2013-06-18 Qualcomm Incorporated CAVLC enhancements for SVC CGS enhancement layer coding
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
AU2008275229B2 (en) 2007-07-09 2014-11-06 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2007356356A1 (en) 2007-07-12 2009-01-15 Lorcan Michael Murphy A hydroalcoholic fat emulsion and emulsifier for use therein
KR20120031083A (ko) 2009-07-24 2012-03-29 에프. 호프만-라 로슈 아게 교반기 시스템
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム
JP2022506682A (ja) 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
IT201900007998A1 (it) 2019-06-04 2020-12-04 Benelli Armi Spa Calcio per arma

Also Published As

Publication number Publication date
US11078294B2 (en) 2021-08-03
SI2188302T1 (en) 2018-07-31
CN101932591A (zh) 2010-12-29
IL202934B (en) 2019-05-30
ES2941738T3 (es) 2023-05-25
EP3597659B1 (de) 2023-03-01
US10759866B2 (en) 2020-09-01
AU2008275229B2 (en) 2014-11-06
KR20210021144A (ko) 2021-02-24
DK3597659T3 (da) 2023-04-03
US10906986B2 (en) 2021-02-02
EP3597659A1 (de) 2020-01-22
TWI574974B (zh) 2017-03-21
EP2586788A1 (de) 2013-05-01
IL246683A0 (en) 2016-08-31
US8574869B2 (en) 2013-11-05
AU2013203411C9 (en) 2017-02-09
FI3597659T3 (fi) 2023-05-03
JP2018111698A (ja) 2018-07-19
TW200914462A (en) 2009-04-01
HUE046992T2 (hu) 2020-04-28
CN112480255A (zh) 2021-03-12
EP3327026A1 (de) 2018-05-30
BRPI0812603B1 (pt) 2021-06-29
TR201802088T4 (tr) 2018-03-21
EP4219522A3 (de) 2023-09-20
ES2751022T3 (es) 2020-03-30
HRP20230461T3 (hr) 2023-07-21
KR20190140090A (ko) 2019-12-18
US20210188993A1 (en) 2021-06-24
KR20100061442A (ko) 2010-06-07
US20140128575A1 (en) 2014-05-08
CA2691692C (en) 2021-05-18
ES2655474T3 (es) 2018-02-20
US20210095040A1 (en) 2021-04-01
IL237754A0 (en) 2015-05-31
TW201713679A (zh) 2017-04-16
EP4335863A2 (de) 2024-03-13
EP3327026B1 (de) 2019-08-21
PL3327026T3 (pl) 2020-02-28
HUE037633T2 (hu) 2018-09-28
JP6030079B2 (ja) 2016-11-24
KR20160105539A (ko) 2016-09-06
EP4245766A2 (de) 2023-09-20
IL272591A (en) 2020-03-31
BRPI0812603A2 (pt) 2015-03-03
EP4219522A2 (de) 2023-08-02
HUE037162T2 (hu) 2018-08-28
AU2013203411C1 (en) 2017-01-19
SG10201406411XA (en) 2014-11-27
JP6721621B2 (ja) 2020-07-15
AU2013203411B2 (en) 2016-09-08
IL259860A (en) 2018-07-31
US20200317801A1 (en) 2020-10-08
IL237755A0 (en) 2015-05-31
EP4245766A9 (de) 2024-01-24
US20130017598A1 (en) 2013-01-17
US10808037B1 (en) 2020-10-20
CN101932591B (zh) 2018-02-16
TWI666217B (zh) 2019-07-21
PT3327026T (pt) 2019-10-30
JP5687057B2 (ja) 2015-03-18
DK3327026T3 (da) 2019-10-28
MX2010000196A (es) 2010-04-21
KR20150042305A (ko) 2015-04-20
SG10201913363VA (en) 2020-03-30
WO2009009523A2 (en) 2009-01-15
TW201942127A (zh) 2019-11-01
SI3327026T1 (sl) 2019-11-29
EP2586788B1 (de) 2017-11-29
KR101643514B1 (ko) 2016-07-27
ES2659829T3 (es) 2018-03-19
CA3113365A1 (en) 2009-01-15
KR20180042457A (ko) 2018-04-25
US20230365704A1 (en) 2023-11-16
IL237755B (en) 2020-02-27
LT3327026T (lt) 2019-11-11
KR102262298B1 (ko) 2021-06-07
HRP20191905T1 (hr) 2020-01-24
CN107090017A (zh) 2017-08-25
WO2009009523A3 (en) 2009-05-14
LT3597659T (lt) 2023-05-10
EP4245766A3 (de) 2024-01-17
US20200347145A1 (en) 2020-11-05
KR102055873B1 (ko) 2019-12-13
HRP20180673T1 (hr) 2018-06-01
JP2017046706A (ja) 2017-03-09
MX354993B (es) 2018-03-28
SG10202005450PA (en) 2020-07-29
JP2010533192A (ja) 2010-10-21
US20230383004A1 (en) 2023-11-30
US20090053786A1 (en) 2009-02-26
JP2014129358A (ja) 2014-07-10
SI3597659T1 (sl) 2023-04-28
AU2013203411B9 (en) 2017-02-09
AU2013203411A1 (en) 2013-05-02
PL2586788T3 (pl) 2018-05-30
AU2008275229A1 (en) 2009-01-15
PL3597659T3 (pl) 2023-07-10
PT3597659T (pt) 2023-04-04
EP2188302A2 (de) 2010-05-26
TW202124409A (zh) 2021-07-01
US20190135935A1 (en) 2019-05-09
US11639395B2 (en) 2023-05-02
HUE061746T2 (hu) 2023-08-28
PL2188302T3 (pl) 2018-04-30
US20170313780A1 (en) 2017-11-02
EP2188302B1 (de) 2017-11-01
KR101851580B1 (ko) 2018-04-25
JP2020105180A (ja) 2020-07-09
CA2691692A1 (en) 2009-01-15
TWI702225B (zh) 2020-08-21
SI2586788T1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
DE17196350T1 (de) Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
HRP20200768T1 (hr) Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
US20210230658A1 (en) Methods of protein production
JP5885864B2 (ja) 陽イオン交換クロマトグラフィーによる抗体の精製
JP2013501522A5 (de)
JP4319979B2 (ja) タンパク質の非アフィニティ精製
EP1404813A2 (de) Verfahren zur kultivierung tierischer zellen und polypeptidproduktion in tierischen zellen
JP2023511291A (ja) 培養細胞から生産された生体物質を連続的に収穫するための装置及び方法
AU2012227163B2 (en) Antibody purification by cation exchange chromatography
AU2015218432A1 (en) Antibody purification by cation exchange chromatography